Pelvic Floor Symptoms Across Menopausel Stages
7 de julio de 2026 actualizado por: Betül Çınar, Bezmialem Vakif University
Comparison of Lower Urinary Tract Symptoms, Bowel Function, and Sexual Health Across Menopausal Stages in Women
The menopausal transition is associated with substantial hormonal alterations that may adversely affect lower urinary tract function, bowel function, and sexual health. Although these symptoms are common, few studies have comprehensively evaluated all three pelvic floor compartments across different menopausal stages.
The aim of this study is to compare lower urinary tract symptoms, bowel symptoms, and female sexual function among women in the perimenopausal, early postmenopausal, and late postmenopausal stages. In addition, the relationship between menopausal stage and symptom severity will be investigated.
Descripción general del estudio
Estado
Aún no reclutando
Condiciones
Descripción detallada
Menopause is characterized by estrogen deficiency, resulting in structural and functional alterations in pelvic floor tissues. Lower urinary tract symptoms, bowel dysfunction, and female sexual dysfunction are increasingly recognized as important health concerns during the menopausal transition.
Despite growing evidence regarding individual pelvic floor disorders, few studies have simultaneously evaluated urinary, colorectal, and sexual symptoms across different menopausal stages.
This study will classify women according to STRAW+10 criteria into:
Perimenopause Early postmenopause Late postmenopause
Participants will undergo a single assessment session. Demographic information together with validated questionnaires will be collected. No intervention or treatment will be provided.
Tipo de estudio
De observación
Inscripción (Estimado)
180
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Betul CINAR, PhD
- Número de teléfono: +905327879969
- Correo electrónico: betulbirik@gmail.com
Copia de seguridad de contactos de estudio
- Nombre: Betul Cinar, PhD
- Número de teléfono: 4649 +90 212 523 22 88
- Correo electrónico: bcinar@bezmialem.edu.tr
Ubicaciones de estudio
-
-
-
Istanbul, Turquía (Türkiye)
- Bezmialem Vakif University
-
Contacto:
- Betul Cinar, PhD
- Número de teléfono: 4649 +90 212 523 22 88
- Correo electrónico: bcinar@gmail.com
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
No
Método de muestreo
Muestra no probabilística
Población de estudio
Women aged 40-65 years attending the Gynecology and Obstetrics Outpatient Clinic who are classified as perimenopausal, early postmenopausal, or late postmenopausal according to the STRAW+10 criteria.
Participants must have an intact uterus and at least one ovary and be able to read and understand Turkish.
Descripción
Inclusion Criteria:
- Female
- Age 40-65 years
- Intact uterus and at least one ovary
- Perimenopause or postmenopause according to STRAW+10 criteria
- Able to read and understand Turkish
Exclusion Criteria:
- Hormone replacement therapy within the previous 6 months
- Oral contraceptive use
- Antipsychotic medication use
- Previous pelvic surgery
- Neurological or systemic diseases affecting bladder or bowel function
- Active urinary tract or vaginal infection
- Pelvic radiotherapy or chemotherapy history
- Active gynecological or urological malignancy
- Alcohol or substance abuse during the previous year
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Perimenopause
Perimenopausal women according to STRAW+10 criteria
|
Lower urinary tract symptoms will be assessed using the validated Bristol Female Lower Urinary Tract Symptoms questionnaire.
Higher scores indicate greater symptom severity and poorer urinary health-related quality of life.
Bowel symptoms and colorectal-anal distress will be evaluated using the Colorectal Anal Distress Inventory-8.
Higher scores indicate greater symptom severity and distress related to bowel dysfunction.
Constipation severity will be assessed using the Cleveland Clinic Constipation Score.
Higher scores represent more severe constipation symptoms.
Female sexual function will be assessed using the Female Sexual Function Index, a validated questionnaire evaluating desire, arousal, lubrication, orgasm, satisfaction, and pain.
Higher scores indicate better sexual function.
|
|
Early postmenopause
Early postmenopausal women according to STRAW+10 criteria
|
Lower urinary tract symptoms will be assessed using the validated Bristol Female Lower Urinary Tract Symptoms questionnaire.
Higher scores indicate greater symptom severity and poorer urinary health-related quality of life.
Bowel symptoms and colorectal-anal distress will be evaluated using the Colorectal Anal Distress Inventory-8.
Higher scores indicate greater symptom severity and distress related to bowel dysfunction.
Constipation severity will be assessed using the Cleveland Clinic Constipation Score.
Higher scores represent more severe constipation symptoms.
Female sexual function will be assessed using the Female Sexual Function Index, a validated questionnaire evaluating desire, arousal, lubrication, orgasm, satisfaction, and pain.
Higher scores indicate better sexual function.
|
|
Late postmenopause
Late postmenopausal women according to STRAW+10 criteria
|
Lower urinary tract symptoms will be assessed using the validated Bristol Female Lower Urinary Tract Symptoms questionnaire.
Higher scores indicate greater symptom severity and poorer urinary health-related quality of life.
Bowel symptoms and colorectal-anal distress will be evaluated using the Colorectal Anal Distress Inventory-8.
Higher scores indicate greater symptom severity and distress related to bowel dysfunction.
Constipation severity will be assessed using the Cleveland Clinic Constipation Score.
Higher scores represent more severe constipation symptoms.
Female sexual function will be assessed using the Female Sexual Function Index, a validated questionnaire evaluating desire, arousal, lubrication, orgasm, satisfaction, and pain.
Higher scores indicate better sexual function.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Bristol Female Lower Urinary Tract Symptoms (BFLUTS) Score
Periodo de tiempo: Baseline (single assessment)
|
Lower urinary tract symptoms will be assessed using the validated Bristol Female Lower Urinary Tract Symptoms questionnaire.
Higher scores indicate greater symptom severity and poorer urinary health-related quality of life
|
Baseline (single assessment)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Colorectal Anal Distress Inventory-8 (CRADI-8)
Periodo de tiempo: Baseline (single assessment)
|
Bowel symptoms and colorectal-anal distress will be evaluated using the Colorectal Anal Distress Inventory-8.
Higher scores indicate greater symptom severity and distress related to bowel dysfunction.
|
Baseline (single assessment)
|
|
Cleveland Clinic Constipation Score
Periodo de tiempo: Baseline (single assessment)
|
Constipation severity will be assessed using the Cleveland Clinic Constipation Score.
Higher scores represent more severe constipation symptoms.
|
Baseline (single assessment)
|
|
Female Sexual Function Index
Periodo de tiempo: Baseline (single assessment)
|
Female sexual function will be assessed using the Female Sexual Function Index, a validated questionnaire evaluating desire, arousal, lubrication, orgasm, satisfaction, and pain.
Higher scores indicate better sexual function.
|
Baseline (single assessment)
|
|
Bristol Stool Form Scale
Periodo de tiempo: Baseline (single assessment)
|
The Bristol Stool Form Scale is a 7-category scale ranging from Type 1 (hard stools) to Type 7 (watery stools).
Values range from 1 to 7. Lower scores indicate harder stool consistency, whereas higher scores indicate looser stool consistency.
|
Baseline (single assessment)
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Silla de estudio: Betul Cinar, PhD, Bezmialem Vakif University
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Estimado)
6 de julio de 2026
Finalización primaria (Estimado)
6 de septiembre de 2026
Finalización del estudio (Estimado)
6 de octubre de 2026
Fechas de registro del estudio
Enviado por primera vez
1 de julio de 2026
Primero enviado que cumplió con los criterios de control de calidad
1 de julio de 2026
Publicado por primera vez (Actual)
8 de julio de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
9 de julio de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
7 de julio de 2026
Última verificación
1 de julio de 2026
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- bvubcinar05
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
INDECISO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .